# Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia

> **NCT03537131** · PHASE2 · TERMINATED · sponsor: **University of Oxford** · enrollment: 9 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet

## Key facts

- **NCT ID:** NCT03537131
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-02
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Temporary halt due to COVID-19 pandemic
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537131, "Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03537131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*